China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen ...

Harbour BioMed launches Élancé Therapeutics to advance next-generation obesity therapies: Cambridge, Massachusetts Thursday, March 13, 2025, 18:00 Hrs [IST] Harbour BioMed, a gl ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company specializing in novel antibody therapeutics for immunology ...

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Harbour BioMed (HKEX: 02142) has appointed Michael Patten as chief strategy officer, responsible for overseeing global ...

Patten will also serve as the Head of Global Alliance and lead efforts to manage and strengthen the company’s partner network ...

Harbour Biomed Ltd. has announced the launch of Élancé Therapeutics with an aim to improve the treatment of obesity. Élancé ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and ...

Michael D. Patten as Chief Strategy Officer.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 12, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...